EP2104113A1 - Process for producing radioactive molybdenum, apparatus therefor and radioactive molybdenum produced by the process - Google Patents
Process for producing radioactive molybdenum, apparatus therefor and radioactive molybdenum produced by the process Download PDFInfo
- Publication number
- EP2104113A1 EP2104113A1 EP07830597A EP07830597A EP2104113A1 EP 2104113 A1 EP2104113 A1 EP 2104113A1 EP 07830597 A EP07830597 A EP 07830597A EP 07830597 A EP07830597 A EP 07830597A EP 2104113 A1 EP2104113 A1 EP 2104113A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- solution
- water
- dissolved
- natural isotopic
- isotopic ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/02—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
- G21G2001/0036—Molybdenum
Definitions
- the present invention relates to an efficient manufacturing method of radioactive molybdenum 99 Mo which is parent nuclide of radioactive technetium ( 99m Tc) used as the radioactive diagnosis medicine.
- the life time (Half period) of radioactive technetium ( 99m Tc) used in large quantities around the world to diagnose cancer or disease of internal organs, or to inspect the function of internal organs is 6.0 hours, and it is short. Therefore, radioactive technetium 99m Tc obtained by manufacturing radioactive molybdenum 99 Mo which is the parent nuclide, and extracting from 99 Mo (Half period is 66 hours) manufactured is usually used for the medical diagnosis etc.
- neutrons are irradiated to powdered or pelletized molybdenum oxide (MoO 3 ) of a solid state, which is Mo compound of a natural isotope to cause the nuclear reaction of 98 Mo(n, ⁇ ) 99 Mo (Hereinafter, this nuclear reaction is called the (n, ⁇ ) reaction or (n, ⁇ ) method).
- MoO 3 molybdenum oxide
- this nuclear reaction is called the (n, ⁇ ) reaction or (n, ⁇ ) method.
- 99 Mo whose specific radioactivity is very low in comparison with the nuclear fission method in which uranium is used as a raw material is produced.
- 99 Mo is generally produced by using powdered or pelletized molybdenum oxide (MoO 3 ) of a solid state as a raw material, enclosing the raw material with a closed container, inserting it into a nuclear reactor by using material irradiation equipment of the nuclear reactor, picking up the material irradiation equipment after irradiating neutrons for a fixed period of time (In general, 5-7 days), opening the closed container picked up, and making its contents ( 99 Mo is generated in MoO 3 , and they exist together) react, for instance, with caustic soda or aqueous ammonium, and dissolving them.
- MoO 3 molybdenum oxide
- the conventional equipment which irradiates the solid MoO 3 raw material is very expensive, the manufacturing ability is low, and a new container is required every time the (metallic) irradiation container where a MoO 3 raw material is enclosed is irradiated, in addition, because the container itself is made radiation after using (irradiating) and becomes radioactive contamination waste, there is the problem that the radioactive contamination waste increases further according to the increase in an amount of manufacturing of 99 Mo.
- the above-mentioned problem is solved by manufacturing 99 Mo by changing the state of Mo compound to which neutrons are irradiated in a nuclear reactor from a solid state into a solution state.
- a method of manufacturing radioactive molybdenum comprising the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98 Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98 Mo is concentrated more than the natural isotopic ratio is dissolved in water to produce 99 Mo in the Mo solution by the radioactivation of 98 Mo, and collecting the Mo solution to obtain 99 Mo.
- 99 Mo is obtained by collecting the Mo solution in continuous or batch processing, for instance, by circulating or feeding Mo solution, and generating 99 Mo in the Mo solution by the radioactivation of 98 Mo.
- a method of manufacturing radioactive molybdenum comprising the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98 Mo of the natural isotopic ratio or Mo compound in which 98 Mo is concentrated more than the natural isotopic ratio is dissolved in water, wherein the Mo compound is ammonium molybdate.
- a method of manufacturing 99 Mo according to the first or second aspect which comprises the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98 Mo of the natural isotopic ratio or Mo compound in which 98 Mo is concentrated more than the natural isotopic ratio is dissolved in water
- the method further comprises the steps of extracting continuously or periodically hydrogen and oxygen gases generated by the radiolysis of water when neutrons are irradiated to the Mo solution in the nuclear reactor, and purging the hydrogen and oxygen with inert gas to dispose of them.
- another manufacturing method comprises the steps of collecting after reuniting the hydrogen and oxygen with catalyst to return to water, and collecting to remove hydrogen and oxygen obtained by decomposing in radiation the water.
- an apparatus for manufacturing radioactive molybdenum in which 99 Mo is obtained by collecting the Mo solution in continuous or batch processing after generating 99 Mo in the Mo solution by circulating the Mo solution in the nuclear reactor, in order to irradiate neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98 Mo of the natural isotopic ratio is dissolved in water or Mo solution in which 98 Mo is concentrated more than the natural isotopic ratio is dissolved in water and thereby radioactivating 98 Mo, which comprises a fluid pass-through type irradiation capsule installed in a reactor core, and a means for generating and collecting 99 Mo in continuous or batch processing by circulating the Mo solution in the capsule.
- an apparatus for manufacturing radioactive molybdenum having the function of generating and collecting 99 Mo in continuous or batch processing by circulating Mo solution in which Mo compound containing 98 Mo of the natural isotopic ratio is dissolved in water or Mo solution in which 98 Mo is concentrated more than the natural isotopic ratio is dissolved in water in a fluid pass-through type irradiation capsule installed in a reactor core which comprises: injection equipment which injects a fixed amount of Mo solution in continuous or batch processing; collecting equipment which collects 99 Mo generated in continuous or batch processing; equipment which extracts and removes hydrogen and oxygen of the gas generated by radiolysis reaction of the water generated in the irradiation capsule; a storage facility in which catalyst which has function to return the hydrogen and oxygen of the extracted gas to water by recombination reaction is filled, circulation equipment of the Mo solution to which a heat exchanger to do cooling in the irradiation capsule is attached; equipment which picks up and collects 99 Mo generated in continuous or batch processing, measuring equipment by which amounts of
- a method of manufacturing radioactive molybdenum comprising the steps of circulating Mo solution in which Mo compound containing 98 Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98 Mo is concentrated more than the natural isotopic ratio is dissolved in water in a nuclear reactor to produce 99 Mo in the Mo solution by radioactivating 98 Mo, and collecting the Mo solution in continuous or batch processing to obtain 99 Mo.
- the present invention uses an irradiation capsule which is far low-cost compared with the conventional high-cost irradiation equipment. According to the present invention, it is possible to increase the manufacturing ability of 99 Mo and manufacture it in continuous or batch processing.
- the desired 99 Mo can be manufactured only by installing a fluid pass-through type capsule which can inject and collect solution from the outside and by injecting the solution into it in continuous or batch processing, the radioactive contamination waste generated when manufacturing 99 Mo by using the conventional irradiation equipment is not generated. Moreover, because the Mo solution which contains 99 Mo generated can be shipped only by dispensing and collecting it in a special container like a vial container made of glass without processing after collecting it, the entire process from the stock of raw material to the collection of 99 Mo which is specified substance can be simplified compared with the prior art.
- the present invention has feature that 99 Mo manufacturing cost is cheaper.
- the complex operations are accompanied when the raw material is palletized. And The difficulty is attended to the management and the maintenance of the quality, because impurities are apt to be mixed at the pelletizing operation.
- the Mo solution which is the raw material used in the present invention it is possible to adjust just by dissolving Mo compound to high purity water by maintaining the high purity Mo compound (ammonium molybdate) used. Because impurities can be absorbed and removed just by causing to flow into an aluminum column, et al. even when they are in the Mo solution, it is easy for the Mo solution irradiation method to maintain high quality because the adjustment of the irradiation body raw material is easy, compared with the solid MoO 3 irradiation method.
- a solid irradiation if the MoO 3 irradiation body is in a powder form, it is necessary to seal up first the irradiation body in a quartz tube, and then enclose in a metallic irradiation container (In general, aluminum family metal). If the MoO 3 irradiation body is in a pelletized form, the sealing up and the enclosing is performed directly in the metallic irradiation container. These irradiation containers become radioactive contamination waste because they are radioactivated by neutron irradiation.
- a Mo solution irradiation method of the present invention includes only an operation that a constant amount of Mo solution is injected with the pump through piping to an irradiation capsule in continuous or batch processing. An irradiation container is unnecessary. Therefore, the radioactive contamination waste is not generated along with 99 Mo manufacturing.
- the 99 Mo manufacturing ability by the solid irradiation method in material testing reactor JMTR of Japan Atomic Energy Agency is 220Ci( 99 Mo)/week, for instance, even when existing facility is remodeled. In addition, it is total 570Ci ( 99 Mo)/week even when expanded. Moreover, about 700 million yen to 1.5 billion yen is necessary according to the calculation as those remodeling cost and installation cost.
- the manufacturing ability of 569Ci( 99 Mo)/week in one system which is almost equal to the solid irradiation method, that is, substantially the same manufacturing ability as the above-mentioned expanded facility in the solid irradiation method can be obtained only by circulating 28% solution of ammonium molybdate to the capsule with the zone of 55 mm in inside diameter ⁇ and 700 mm in height to which neutrons are irradiated (effective content volume 1.66L) at the rate of 277mUday.
- the provisional calculation of the installation cost is about 200 million yen a system. Accordingly, the present invention is superior to the conventional method also in 99 Mo manufacturing ability and the installation cost.
- the conventional solid irradiation method it is manufactured by inserting an irradiation container into a nuclear reactor with material irradiation equipment, picking up after irradiating neutrons for a fixed period of time (generally, for 5 to 7 days), opening the closed container picked up, and making its contents ( 99 Mo is generated in MoO 3 , and they exist together) react, for instance, with alkaline solution such as caustic soda, aqueous ammonium and dissolving them.
- alkaline solution such as caustic soda, aqueous ammonium and dissolving them.
- the process to bring into the state which can be shipped as 99 Mo is complex because it is impossible to replace the irradiation body on its way, and it is necessary to open the MoO 3 irradiation body which contains 99 Mo in another facility and dissolve.
- the Mo solution which contains 99 Mo can be collected only by activating the pump of 99 Mo collection equipment in the Mo solution irradiation method according to the present invention.
- the Mo solution which contains 99 Mo generated can be shipped only by dispensing and collecting it in a container as it is, the entire process from the stock of raw material to the collection of 99 Mo product can be simplified.
- radioactive substance according to the present invention which is socially useful can be used to manufacture other radioactive substance.
- life time of radioactive rhenium ( 188 Re) which can be used to treat cancers is short (The half period of 188 Re is 17.5 hours)
- radioactive tungsten 188 W which is parent nuclide of 188 Re is manufactured, 188 Re extracted from the 188 W can be used for cancer care.
- efficiently manufacturing the aimed 188 W becomes possible by irradiating neutrons in a nuclear reactor to W solution in which W compound containing 186 W of the natural isotopic ratio is dissolved in water, or W solution in which 186 W is concentrated more than the natural isotopic ratio is dissolved in water, carrying out two step reaction of 186 W(n, ⁇ ) 187 W ⁇ 187 W(n, ⁇ ) 188 W to produce 188 W in the W solution, and by collecting the W solution in continuous or batch processing. Or it becomes possible by circulating or feeding W solution, radioactivating 186 W to generate 188 W in the W solution, and by collecting the W solution in continuous or batch processing.
- FIG. 1 An embodiment of this invention is shown in FIG. 1 .
- Capsule4 for solution irradiation is set up in the core of a nuclear reactor. This capsule is connected with external Mo solution injection equipment (6, 7, 8) and generation 99 Mo collection container 11 via pipe 9 through which the Mo solution is introduced and pipe 10 through which the Mo solution is collected. Ammonium molybdate solution is adjusted, and stored in a container of Mo solution supplying system 6 beforehand.
- the Mo solution is injected into the irradiation capsule via pipe 9 by pump 7.
- the irradiation time of the Mo solution in the capsule by neutrons can be adjusted by injecting the Mo solution in continuous or batch processing. Though time for irradiating neutrons to the Mo solution is needed for 5-7 days, the gas generated by the radiolysis of water and the heat generated by the irradiation of the capsule in the core can be removed by circulating the Mo solution in the capsule by the operation of an external valve and circulating pump 8 into the system to remove hydrogen gas and oxygen gas generated by the radiolysis of water in heat exchanger 13 and extraction gas processing system 14.
- a constant amount of the Mo solution irradiated by a predetermined amount of neutrons can be collected into 99 Mo collection container 11 to obtain 99 Mo. Because 99 Mo with a high radioactivity is collected into this container 11, it is necessary to cover the radiation such as gamma rays discharged from there with lead etc. and reduce the radiation exposure of workers. It is also possible to automate 99 Mo collection operation because 99 Mo can be collected only by the operation of pumps 8 and 15.
- the hydrogen gas and the oxygen gas generated by the radiolysis of water of the Mo solution in the capsule whose content volume is 1.66L are respectively 0.18NL and 0.09NL per day, which are few. However, because these gases are in danger of returning to the system, they are removed by extracting in extraction gas processing system 14 when the Mo solution is circulated or collected.
- These hydrogen and oxygen gases can be discharged outside of the system by purging with inert gas such as nitrogen gas or helium gas for instance, or returned to the Mo solution after returning to the state of water by reuniting the hydrogen and the oxygen by using the catalyst,
- the Mo solution collected to 99 Mo collection container 11 is transported to 99 Mo dispensation unit 117, and is dispensed in 99 Mo shipping container like a vial.
- the 99 Mo shipping container is put in the transport container with radiation shield as it is, and shipped as 99 Mo product after packed.
- the present invention it becomes possible to manufacture efficiently parent nuclide 99 Mo of 99m Tc daily used in large quantities for the medical treatment diagnosis in the world including Japan becomes possible according to the present invention.
- 99 Mo the most is manufactured by a method of making highly enriched uranium a raw material now.
- the (n, ⁇ ) method which does not use the uranium as a raw material is going to be used because the conventional nuclear fission method, in which uranium is used as a raw material, has the problem described above.
- a large amount of 99 Mo is manufactured by using the (n, ⁇ ) method according to the present invention, enormous social contribution becomes possible.
Landscapes
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plasma & Fusion (AREA)
- High Energy & Nuclear Physics (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Monitoring And Testing Of Nuclear Reactors (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Sampling And Sample Adjustment (AREA)
- Compositions Of Oxide Ceramics (AREA)
Abstract
Description
- The present invention relates to an efficient manufacturing method of radioactive molybdenum 99Mo which is parent nuclide of radioactive technetium (99mTc) used as the radioactive diagnosis medicine.
- The life time (Half period) of radioactive technetium (99mTc) used in large quantities around the world to diagnose cancer or disease of internal organs, or to inspect the function of internal organs is 6.0 hours, and it is short. Therefore, radioactive technetium 99mTc obtained by manufacturing radioactive molybdenum 99Mo which is the parent nuclide, and extracting from 99Mo (Half period is 66 hours) manufactured is usually used for the medical diagnosis etc.
- 99Mo is obtained so far by irradiating neutrons to highly enriched uranium obtained by concentrating 235U to about 95% in a nuclear reactor to cause the nuclear fission reaction, and extracting 99Mo from the fission products. There is especially a problem in the viewpoint of the nuclear non-proliferation with regard to the method of using the enriched uranium. Therefore, International Atomic Energy Agency (IAEA) appeals every country in the world to use low enriched uranium (235U) of 20% or less, and the technological development therefor is advanced in the world now. However, if the low enriched uranium in which the uranium enrichment is adjusted to 20% or less is used as a raw material for 99Mo manufacturing, a large amount of radioactive waste generated along with the fission reaction is produced. In particular, the problem that the formation of plutonium increases approximately twenty-fivefold is newly presented. For that reason, the nuclear fission method which uses the uranium as a raw material to manufacture 99Mo is reviewed.
- The above-mentioned problem is raised in the method of using uranium as a raw materias for 99 Mo manufacturing. However, as a method of not using uranium as a raw material for 99 Mo manufacturing, 99Mo manufacturing by a (n, γ) method has been put to practical use, in which neutron beams are irradiated to a solid material which is Mo compound of concentrated 98Mo or natural Mo compound in a nuclear reactor. Here, in a nuclear reactor, neutrons are irradiated to powdered or pelletized molybdenum oxide (MoO3) of a solid state, which is Mo compound of a natural isotope to cause the nuclear reaction of 98Mo(n, γ)99Mo (Hereinafter, this nuclear reaction is called the (n, γ) reaction or (n, γ) method). In this method, only 99Mo whose specific radioactivity is very low in comparison with the nuclear fission method in which uranium is used as a raw material is produced. This method is examined so far as a method of having an advantage not to generate the radioactive waste according to nuclear fission like a uranium method and to manufacture at a low cost, and it has been put to practical use as a gel method 99mTc generator now. However, the gel method 99mTc generator of a (n, γ) method has not come to spread widely because of problems on the reproducibility in the manufacturing and on the quality side especially.
- Because the specific radioactivity of 99Mo manufactured by the (n, γ) method is low, the technology which collects 99mTc by a conventional, small column type one is not able to be put to practical use. However, as is described in
JP 8-309182 A1 JP 10-30027 A1 - In a current (n, γ) method, 99Mo is generally produced by using powdered or pelletized molybdenum oxide (MoO3) of a solid state as a raw material, enclosing the raw material with a closed container, inserting it into a nuclear reactor by using material irradiation equipment of the nuclear reactor, picking up the material irradiation equipment after irradiating neutrons for a fixed period of time (In general, 5-7 days), opening the closed container picked up, and making its contents (99Mo is generated in MoO3, and they exist together) react, for instance, with caustic soda or aqueous ammonium, and dissolving them. However, there are problems that the adjustment and the QC (quality control) of molybdenum oxide as the raw materials are complex, and the manufacturing ability of 99Mo is low because it is necessary continuously to irradiate the same irradiation body while irradiating for a fixed period of time and therefore the irradiation body containing the raw material cannot be replaced.
- Because the conventional equipment which irradiates the solid MoO3 raw material is very expensive, the manufacturing ability is low, and a new container is required every time the (metallic) irradiation container where a MoO3 raw material is enclosed is irradiated, in addition, because the container itself is made radiation after using (irradiating) and becomes radioactive contamination waste, there is the problem that the radioactive contamination waste increases further according to the increase in an amount of manufacturing of 99Mo. In the present invention, the above-mentioned problem is solved by manufacturing 99Mo by changing the state of Mo compound to which neutrons are irradiated in a nuclear reactor from a solid state into a solution state.
- According to a first aspect of the present invention, a method of manufacturing radioactive molybdenum comprising the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water to produce 99Mo in the Mo solution by the radioactivation of 98Mo, and collecting the Mo solution to obtain 99Mo.
- More concretely, 99Mo is obtained by collecting the Mo solution in continuous or batch processing, for instance, by circulating or feeding Mo solution, and generating 99Mo in the Mo solution by the radioactivation of 98Mo.
- According to a second aspect of the present invention, a method of manufacturing radioactive molybdenum comprising the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio or Mo compound in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water, wherein the Mo compound is ammonium molybdate.
- According to a third aspect of the present invention, in a method of manufacturing 99Mo according to the first or second aspect, which comprises the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio or Mo compound in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water, the method further comprises the steps of extracting continuously or periodically hydrogen and oxygen gases generated by the radiolysis of water when neutrons are irradiated to the Mo solution in the nuclear reactor, and purging the hydrogen and oxygen with inert gas to dispose of them.
- Moreover, another manufacturing method according to the same aspect comprises the steps of collecting after reuniting the hydrogen and oxygen with catalyst to return to water, and collecting to remove hydrogen and oxygen obtained by decomposing in radiation the water.
- According to a fourth aspect of the present invention, an apparatus for manufacturing radioactive molybdenum, in which 99Mo is obtained by collecting the Mo solution in continuous or batch processing after generating 99Mo in the Mo solution by circulating the Mo solution in the nuclear reactor, in order to irradiate neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water and thereby radioactivating 98Mo, which comprises a fluid pass-through type irradiation capsule installed in a reactor core, and a means for generating and collecting 99Mo in continuous or batch processing by circulating the Mo solution in the capsule.
- According to a fifth aspect of the present invention, an apparatus for manufacturing radioactive molybdenum having the function of generating and collecting 99Mo in continuous or batch processing by circulating Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water in a fluid pass-through type irradiation capsule installed in a reactor core, which comprises: injection equipment which injects a fixed amount of Mo solution in continuous or batch processing; collecting equipment which collects 99Mo generated in continuous or batch processing; equipment which extracts and removes hydrogen and oxygen of the gas generated by radiolysis reaction of the water generated in the irradiation capsule; a storage facility in which catalyst which has function to return the hydrogen and oxygen of the extracted gas to water by recombination reaction is filled, circulation equipment of the Mo solution to which a heat exchanger to do cooling in the irradiation capsule is attached; equipment which picks up and collects 99Mo generated in continuous or batch processing, measuring equipment by which amounts of the generation and the collection of 99Mo are measured, and a shielding facility to shield the radiation such as gamma rays generated from 99Mo generated and collected and 99mTc of the coexisting daughter nuclide.
- According to a sixth aspect of the present invention, a method of manufacturing radioactive molybdenum comprising the steps of circulating Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water in a nuclear reactor to produce 99Mo in the Mo solution by radioactivating 98Mo, and collecting the Mo solution in continuous or batch processing to obtain 99Mo.
- The present invention uses an irradiation capsule which is far low-cost compared with the conventional high-cost irradiation equipment. According to the present invention, it is possible to increase the manufacturing ability of 99Mo and manufacture it in continuous or batch processing.
- Because in the present invention, the desired 99Mo can be manufactured only by installing a fluid pass-through type capsule which can inject and collect solution from the outside and by injecting the solution into it in continuous or batch processing, the radioactive contamination waste generated when manufacturing 99Mo by using the conventional irradiation equipment is not generated. Moreover, because the Mo solution which contains 99Mo generated can be shipped only by dispensing and collecting it in a special container like a vial container made of glass without processing after collecting it, the entire process from the stock of raw material to the collection of 99Mo which is specified substance can be simplified compared with the prior art.
- As mentioned above, because the facility cost is cheap, the radioactive contamination waste is not generated according to manufacturing, and the entire manufacturing process is easier, the present invention has feature that 99Mo manufacturing cost is cheaper.
- Although powdered or pelletized molybdenum oxide (MoO3) is used in a conventional solid irradiation method, It is preferable that the solution dissolving operation after the irradiation is carried out in palletized forms, because a large amount of 99Mo is generated after the neutron irradiation. The reason is that there is a fear that the powder disperses, and spills at the stage of the operation by which it is dissolved in case of the powder which contains a large amount of radioactive 99Mo, and the work area might be polluted with radioactive substance (99Mo).
- The complex operations are accompanied when the raw material is palletized. And The difficulty is attended to the management and the maintenance of the quality, because impurities are apt to be mixed at the pelletizing operation. On the other hand, as for the Mo solution which is the raw material used in the present invention, it is possible to adjust just by dissolving Mo compound to high purity water by maintaining the high purity Mo compound (ammonium molybdate) used. Because impurities can be absorbed and removed just by causing to flow into an aluminum column, et al. even when they are in the Mo solution, it is easy for the Mo solution irradiation method to maintain high quality because the adjustment of the irradiation body raw material is easy, compared with the solid MoO3 irradiation method.
- With regard to a solid irradiation, if the MoO3 irradiation body is in a powder form, it is necessary to seal up first the irradiation body in a quartz tube, and then enclose in a metallic irradiation container (In general, aluminum family metal). If the MoO3 irradiation body is in a pelletized form, the sealing up and the enclosing is performed directly in the metallic irradiation container. These irradiation containers become radioactive contamination waste because they are radioactivated by neutron irradiation. On the other hand, a Mo solution irradiation method of the present invention includes only an operation that a constant amount of Mo solution is injected with the pump through piping to an irradiation capsule in continuous or batch processing. An irradiation container is unnecessary. Therefore, the radioactive contamination waste is not generated along with 99Mo manufacturing.
- The 99Mo manufacturing ability by the solid irradiation method in material testing reactor JMTR of Japan Atomic Energy Agency is 220Ci(99Mo)/week, for instance, even when existing facility is remodeled. In addition, it is total 570Ci (99Mo)/week even when expanded. Moreover, about 700 million yen to 1.5 billion yen is necessary according to the calculation as those remodeling cost and installation cost. According to the solution irradiation capsule of the present invention, the manufacturing ability of 569Ci(99Mo)/week in one system, which is almost equal to the solid irradiation method, that is, substantially the same manufacturing ability as the above-mentioned expanded facility in the solid irradiation method can be obtained only by circulating 28% solution of ammonium molybdate to the capsule with the zone of 55 mm in inside diameter φ and 700 mm in height to which neutrons are irradiated (effective content volume 1.66L) at the rate of 277mUday. Moreover, the provisional calculation of the installation cost is about 200 million yen a system. Accordingly, the present invention is superior to the conventional method also in 99Mo manufacturing ability and the installation cost.
- Next, 99Mo manufacturing processes will be compared. In the conventional solid irradiation method, it is manufactured by inserting an irradiation container into a nuclear reactor with material irradiation equipment, picking up after irradiating neutrons for a fixed period of time (generally, for 5 to 7 days), opening the closed container picked up, and making its contents (99Mo is generated in MoO3, and they exist together) react, for instance, with alkaline solution such as caustic soda, aqueous ammonium and dissolving them. Therefore, the process to bring into the state which can be shipped as 99Mo is complex because it is impossible to replace the irradiation body on its way, and it is necessary to open the MoO3 irradiation body which contains 99Mo in another facility and dissolve. On the other hand, the Mo solution which contains 99Mo can be collected only by activating the pump of 99Mo collection equipment in the Mo solution irradiation method according to the present invention. In addition, because the Mo solution which contains 99Mo generated can be shipped only by dispensing and collecting it in a container as it is, the entire process from the stock of raw material to the collection of 99Mo product can be simplified.
- Further, the efficient manufacturing method of radioactive substance according to the present invention, which is socially useful can be used to manufacture other radioactive substance. For example, because the life time of radioactive rhenium (188Re) which can be used to treat cancers is short (The half period of 188Re is 17.5 hours), radioactive tungsten 188W which is parent nuclide of 188Re is manufactured, 188Re extracted from the 188W can be used for cancer care. In this case, efficiently manufacturing the aimed 188W becomes possible by irradiating neutrons in a nuclear reactor to W solution in which W compound containing 186W of the natural isotopic ratio is dissolved in water, or W solution in which 186W is concentrated more than the natural isotopic ratio is dissolved in water, carrying out two step reaction of 186W(n, γ)187W → 187W(n, γ)188W to produce 188W in the W solution, and by collecting the W solution in continuous or batch processing. Or it becomes possible by circulating or feeding W solution, radioactivating 186W to generate 188W in the W solution, and by collecting the W solution in continuous or batch processing.
-
-
FIG. 1 is a drawing showing 99Mo manufacturing apparatus of Mo solution circulating type according to one embodiment of the present invention. - An embodiment of this invention is shown in
FIG. 1 . Capsule4 for solution irradiation is set up in the core of a nuclear reactor. This capsule is connected with external Mo solution injection equipment (6, 7, 8) and generation 99Mo collection container 11 viapipe 9 through which the Mo solution is introduced andpipe 10 through which the Mo solution is collected. Ammonium molybdate solution is adjusted, and stored in a container of Mosolution supplying system 6 beforehand. - The Mo solution is injected into the irradiation capsule via
pipe 9 by pump 7. The irradiation time of the Mo solution in the capsule by neutrons can be adjusted by injecting the Mo solution in continuous or batch processing. Though time for irradiating neutrons to the Mo solution is needed for 5-7 days, the gas generated by the radiolysis of water and the heat generated by the irradiation of the capsule in the core can be removed by circulating the Mo solution in the capsule by the operation of an external valve and circulatingpump 8 into the system to remove hydrogen gas and oxygen gas generated by the radiolysis of water inheat exchanger 13 and extractiongas processing system 14. - A constant amount of the Mo solution irradiated by a predetermined amount of neutrons can be collected into 99
Mo collection container 11 to obtain 99Mo. Because 99Mo with a high radioactivity is collected into thiscontainer 11, it is necessary to cover the radiation such as gamma rays discharged from there with lead etc. and reduce the radiation exposure of workers. It is also possible to automate 99Mo collection operation because 99Mo can be collected only by the operation ofpumps gas processing system 14 when the Mo solution is circulated or collected. - These hydrogen and oxygen gases can be discharged outside of the system by purging with inert gas such as nitrogen gas or helium gas for instance, or returned to the Mo solution after returning to the state of water by reuniting the hydrogen and the oxygen by using the catalyst, The Mo solution collected to 99
Mo collection container 11 is transported to99Mo dispensation unit 117, and is dispensed in 99Mo shipping container like a vial. The 99Mo shipping container is put in the transport container with radiation shield as it is, and shipped as 99Mo product after packed. - In the Mo solution irradiation method, all processes from the collection of 99Mo to the shipment of 99Mo product can be carried out in a short period of time. Therefore, suppressing the depletion by natural decay of 99Mo (The half period is 66 hours) that the life time is short to the minimum becomes possible.
- According to the present invention, it becomes possible to manufacture efficiently parent nuclide 99Mo of 99mTc daily used in large quantities for the medical treatment diagnosis in the world including Japan becomes possible according to the present invention. As for 99Mo, the most is manufactured by a method of making highly enriched uranium a raw material now. However, the (n, γ) method which does not use the uranium as a raw material is going to be used because the conventional nuclear fission method, in which uranium is used as a raw material, has the problem described above. When a large amount of 99Mo is manufactured by using the (n, γ) method according to the present invention, enormous social contribution becomes possible.
Claims (8)
- A method of manufacturing radioactive molybdenum comprising the steps of:irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water to produce 99Mo in the Mo solution by the radioactivation of 98Mo; andcollecting the Mo solution to obtain 99Mo.
- A method of manufacturing radioactive molybdenum comprising the steps of:circulating or feeding Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water to produce 99Mo in said Mo solution by the radioactivation of 98Mo, andcollecting said Mo solution in continuous or batch processing to obtain 99Mo.
- The method of manufacturing radioactive molybdenum according to claim 1, wherein said Mo compound is ammonium molybdate.
- The method of manufacturing 99Mo according to any one of claims 1 to 3, which comprises the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio or Mo compound in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water, the method further comprises the steps of:extracting continuously or periodically hydrogen and oxygen gases generated by the radiolysis of water when neutrons are irradiated to said Mo solution in the nuclear reactor; andpurging the hydrogen and oxygen with inert gas to dispose of them.
- The method of manufacturing 99Mo according to any one of claims 1 to 3, which comprises the steps of irradiating neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio or Mo compound in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water, the method further comprises the steps of:extracting continuously or periodically hydrogen and oxygen gases generated by the radiolysis of water when neutrons are irradiated to said Mo solution in the nuclear reactor;collecting after reuniting the hydrogen and oxygen with catalyst to return to water; andcollecting hydrogen and oxygen obtained by decomposing in radiation the water to remove them.
- An apparatus for manufacturing radioactive molybdenum, in which 99Mo is obtained by collecting the Mo solution in continuous or batch processing after generating 99Mo in the Mo solution by circulating the Mo solution in a nuclear reactor, in order to irradiate neutrons in a nuclear reactor to Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water and thereby radioactivating 98Mo, which comprises a fluid pass-through type irradiation capsule installed in a reactor core, and a means for generating and collecting 99Mo in continuous or batch processing by causing the Mo solution to flow into the capsule.
- An apparatus for manufacturing radioactive molybdenum having the function of generating and collecting 99Mo in continuous or batch processing by circulating Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water in a fluid pass-through type irradiation capsule installed in a reactor core, which comprises:injection equipment which injects a fixed amount of Mo solution in continuous or batch processing;collecting equipment which collects 99Mo generated in continuous or batch processing;removing equipment which extracts and removes hydrogen and oxygen of the gas generated by radiolysis reaction of the water generated in the irradiation capsule;a storage facility in which catalyst which has function to return the hydrogen and oxygen of the extracted gas to water by recombination reaction is filled;circulation equipment of the Mo solution to which a heat exchanger to do cooling in the irradiation capsule is attached;collecting equipment which picks up and collects 99Mo generated in continuous or batch processing;measuring equipment by which amounts of the generation and the collection of 99Mo are measured; anda shielding facility to shield the radiation such as gamma rays generated from 99Mo generated and collected and 99mTc of the coexisting daughter nuclide.
- A method of manufacturing radioactive molybdenum comprising the steps of circulating Mo solution in which Mo compound containing 98Mo of the natural isotopic ratio is dissolved in water, or Mo solution in which 98Mo is concentrated more than the natural isotopic ratio is dissolved in water in a nuclear reactor to produce 99Mo in the Mo solution by radioactivating 98Mo, and collecting the Mo solution in continuous or batch processing to obtain 99Mo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006286159A JP4618732B2 (en) | 2006-10-20 | 2006-10-20 | Method and apparatus for manufacturing radioactive molybdenum |
PCT/JP2007/070863 WO2008047946A1 (en) | 2006-10-20 | 2007-10-19 | Process for producing radioactive molybdenum, apparatus therefor and radioactive molybdenum produced by the process |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2104113A1 true EP2104113A1 (en) | 2009-09-23 |
EP2104113A4 EP2104113A4 (en) | 2010-09-15 |
EP2104113B1 EP2104113B1 (en) | 2012-01-11 |
Family
ID=39314153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07830597A Not-in-force EP2104113B1 (en) | 2006-10-20 | 2007-10-19 | Process for producing radioactive molybdenum |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2104113B1 (en) |
JP (1) | JP4618732B2 (en) |
AT (1) | ATE541297T1 (en) |
CA (1) | CA2666570C (en) |
WO (1) | WO2008047946A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120027152A1 (en) * | 2010-07-29 | 2012-02-02 | of Oregon State | Isotope production target |
US20120314828A1 (en) * | 2010-02-01 | 2012-12-13 | Arnd Baurichter | METHOD AND DEVICE FOR PRODUCING 99mTc |
US9287015B2 (en) | 2010-02-01 | 2016-03-15 | Siemens Aktiengesellschaft | Method and device for producing two different radioactive isotopes |
RU2666552C1 (en) * | 2017-12-19 | 2018-09-11 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Method of producing nanostructured target for production of molybdenum-99 |
RU2690692C1 (en) * | 2018-11-21 | 2019-06-05 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | METHOD OF PRODUCING NANOSTRUCTURED TARGET FOR PRODUCTION OF RADONUCLIDE Mo-99 |
US20210304914A1 (en) * | 2010-01-28 | 2021-09-30 | SHINE Medical Technologies, LLC | Segmented reaction chamber for radioisotope production |
US20220199277A1 (en) * | 2019-05-09 | 2022-06-23 | Hitachi, Ltd. | Apparatus for producing radionuclide and method for producing radionuclide |
US11830637B2 (en) | 2008-05-02 | 2023-11-28 | Shine Technologies, Llc | Device and method for producing medical isotopes |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2131369A1 (en) * | 2008-06-06 | 2009-12-09 | Technische Universiteit Delft | A process for the production of no-carrier added 99Mo |
CN101685680B (en) * | 2008-09-27 | 2011-11-09 | 中国核动力研究设计院 | Uniform inner heat source simulator of medical isotope production solution reactor |
JP5569834B2 (en) * | 2009-01-30 | 2014-08-13 | 独立行政法人日本原子力研究開発機構 | Method for producing high density, high purity (n, γ) 99Mo |
US8699651B2 (en) * | 2009-04-15 | 2014-04-15 | Ge-Hitachi Nuclear Energy Americas Llc | Method and system for simultaneous irradiation and elution capsule |
JP5427483B2 (en) | 2009-06-19 | 2014-02-26 | 株式会社化研 | Concentration, elution recovery method, and system of radiotechnetium as a raw material for radiopharmaceuticals and their labeled compounds |
JP5403605B2 (en) * | 2009-06-29 | 2014-01-29 | 独立行政法人日本原子力研究開発機構 | Radiation irradiation equipment |
JP5598900B2 (en) * | 2009-11-20 | 2014-10-01 | 独立行政法人日本原子力研究開発機構 | High purity 99mTc concentration method and concentration apparatus |
WO2012039036A1 (en) * | 2010-09-22 | 2012-03-29 | 独立行政法人放射線医学総合研究所 | Process and device for production of radionuclide using accelerator |
KR101138445B1 (en) | 2011-03-04 | 2012-04-26 | 한국원자력연구원 | A method for preparing low enriched and plate shaped uranium target with high density, and low enriched uranium target with high density prepared by the method |
US10734126B2 (en) | 2011-04-28 | 2020-08-04 | SHINE Medical Technologies, LLC | Methods of separating medical isotopes from uranium solutions |
JP5916083B2 (en) * | 2011-12-23 | 2016-05-11 | 株式会社化研 | 99mTc recovery device |
JP5916082B2 (en) * | 2011-12-23 | 2016-05-11 | 株式会社化研 | 99mTc recovery method and 99mTc recovery device |
JP5916084B2 (en) * | 2011-12-23 | 2016-05-11 | 株式会社化研 | Purified Mo solution preparation method for preparation and purified Mo solution preparation apparatus for preparation |
RU2490737C1 (en) * | 2012-03-29 | 2013-08-20 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Method for obtaining molybdenum-99 radioisotope |
KR102172861B1 (en) | 2012-04-05 | 2020-11-02 | 샤인 메디컬 테크놀로지스, 인크. | Aqueous assembly and control method |
WO2014109807A2 (en) * | 2012-12-10 | 2014-07-17 | Ge-Hitachi Nuclear Energy Americas Llc | Systems and methods for harvesting and storing materials produced in a nuclear reactor |
RU2578039C1 (en) * | 2014-12-18 | 2016-03-20 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Method of producing nanostructured target for production of molybdenum-99 radioisotope |
RU2588594C1 (en) * | 2015-06-15 | 2016-07-10 | Российская Федерация, от имени которой выступает Государственная корпорация по атомной энергии "Росатом" | Method of producing nanostructured target for producing molybdenum-99 radioisotopes |
CN106128539B (en) * | 2016-08-30 | 2019-01-22 | 中广核研究院有限公司 | A kind of system producing medical short-lived phase radioactive source using pressurized-water reactor nuclear power plant |
RU2688196C9 (en) * | 2018-07-02 | 2019-07-09 | Акционерное общество "Радиевый институт имени В.Г. Хлопина" | The method of producing radioisotope molybdenum-99 |
RU2735646C1 (en) * | 2020-05-15 | 2020-11-05 | Акционерное Общество "Производственное Объединение "Электрохимический завод" (АО "ПО ЭХЗ") | Method of producing nanostructured target for production of radionuclide molybdenum-99 |
JP2022069253A (en) * | 2020-10-23 | 2022-05-11 | 三菱重工業株式会社 | Production management device, production management method and production management program of radioisotope |
CN114121330B (en) * | 2021-11-11 | 2024-05-14 | 中国核动力研究设计院 | Molybdenum technetium generator, preparation method and device |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522102A (en) * | 1978-08-02 | 1980-02-16 | Japan Atomic Energy Res Inst | Method of making molybdenumm99 by using molybdenum trioxide pellet |
US4990787A (en) * | 1989-09-29 | 1991-02-05 | Neorx Corporation | Radionuclide generator system and method for its preparation and use |
CA2184967A1 (en) * | 1994-11-10 | 1998-03-07 | Russell M. Ball | Medical Isotope Production Reactor |
US6337055B1 (en) * | 2000-01-21 | 2002-01-08 | Tci Incorporated | Inorganic sorbent for molybdenum-99 extraction from irradiated uranium solutions and its method of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2857349B2 (en) | 1995-05-22 | 1999-02-17 | 日本原子力研究所 | Mo adsorbent for 99Mo-99mTc generator and method for producing the same |
JP2862837B2 (en) | 1996-07-16 | 1999-03-03 | 日本原子力研究所 | Mo adsorbent for 99Mo-99mTc generator and method for producing the same |
JP4994589B2 (en) * | 2004-11-08 | 2012-08-08 | 住友重機械工業株式会社 | Target for radioisotope production |
-
2006
- 2006-10-20 JP JP2006286159A patent/JP4618732B2/en not_active Expired - Fee Related
-
2007
- 2007-10-19 CA CA2666570A patent/CA2666570C/en not_active Expired - Fee Related
- 2007-10-19 EP EP07830597A patent/EP2104113B1/en not_active Not-in-force
- 2007-10-19 WO PCT/JP2007/070863 patent/WO2008047946A1/en active Application Filing
- 2007-10-19 AT AT07830597T patent/ATE541297T1/en active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522102A (en) * | 1978-08-02 | 1980-02-16 | Japan Atomic Energy Res Inst | Method of making molybdenumm99 by using molybdenum trioxide pellet |
US4990787A (en) * | 1989-09-29 | 1991-02-05 | Neorx Corporation | Radionuclide generator system and method for its preparation and use |
CA2184967A1 (en) * | 1994-11-10 | 1998-03-07 | Russell M. Ball | Medical Isotope Production Reactor |
US6337055B1 (en) * | 2000-01-21 | 2002-01-08 | Tci Incorporated | Inorganic sorbent for molybdenum-99 extraction from irradiated uranium solutions and its method of use |
Non-Patent Citations (1)
Title |
---|
See also references of WO2008047946A1 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11830637B2 (en) | 2008-05-02 | 2023-11-28 | Shine Technologies, Llc | Device and method for producing medical isotopes |
US20210304914A1 (en) * | 2010-01-28 | 2021-09-30 | SHINE Medical Technologies, LLC | Segmented reaction chamber for radioisotope production |
US11894157B2 (en) * | 2010-01-28 | 2024-02-06 | Shine Technologies, Llc | Segmented reaction chamber for radioisotope production |
US20120314828A1 (en) * | 2010-02-01 | 2012-12-13 | Arnd Baurichter | METHOD AND DEVICE FOR PRODUCING 99mTc |
US9287015B2 (en) | 2010-02-01 | 2016-03-15 | Siemens Aktiengesellschaft | Method and device for producing two different radioactive isotopes |
US9576692B2 (en) | 2010-02-01 | 2017-02-21 | Siemens Aktiengesellschaft | Method and device for producing 99mTc |
US20120027152A1 (en) * | 2010-07-29 | 2012-02-02 | of Oregon State | Isotope production target |
RU2666552C1 (en) * | 2017-12-19 | 2018-09-11 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Method of producing nanostructured target for production of molybdenum-99 |
RU2690692C1 (en) * | 2018-11-21 | 2019-06-05 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | METHOD OF PRODUCING NANOSTRUCTURED TARGET FOR PRODUCTION OF RADONUCLIDE Mo-99 |
US20220199277A1 (en) * | 2019-05-09 | 2022-06-23 | Hitachi, Ltd. | Apparatus for producing radionuclide and method for producing radionuclide |
Also Published As
Publication number | Publication date |
---|---|
EP2104113B1 (en) | 2012-01-11 |
WO2008047946A1 (en) | 2008-04-24 |
CA2666570C (en) | 2011-11-15 |
ATE541297T1 (en) | 2012-01-15 |
CA2666570A1 (en) | 2008-04-24 |
EP2104113A4 (en) | 2010-09-15 |
JP4618732B2 (en) | 2011-01-26 |
JP2008102078A (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2104113B1 (en) | Process for producing radioactive molybdenum | |
AU2015203131B2 (en) | Methods and apparatus for selective gaseous extraction of molybdenum-99 and other fission product radioisotopes | |
US9047997B2 (en) | Techniques for on-demand production of medical isotopes such as Mo-99/Tc-99m and radioactive iodine isotopes including I-131 | |
JP5461435B2 (en) | Method and apparatus for producing radioisotopes or treating nuclear waste | |
JP2006162612A (en) | Isotope producing method | |
KR20130119420A (en) | Primary neutron source multiplier assembly | |
EP3413318B1 (en) | Method for preparing radioactive substance through muon irradiation, and substance prepared using said method | |
Konings et al. | Transmutation of Technetium and Iodine—Irradiation Tests in the Frame of the EFTTRA Cooperation | |
Cackette et al. | 82Sr production from metallic Rb targets and development of an 82Rb generator system | |
Mushtaq et al. | Management of radioactive waste from molybdenum-99 production using low enriched uranium foil target and modified CINTICHEM process | |
Chuvilin et al. | Production of 89Sr in solution reactor | |
CN107622807A (en) | It is a kind of to produce radioisotopic device and method with phot-neutron source | |
Youker et al. | Compendium of Phase-I Mini-SHINE Experiments | |
CN117524534B (en) | System for producing Pu-238 on line by using sodium-cooled fast reactor irradiation loop | |
RU2688196C9 (en) | The method of producing radioisotope molybdenum-99 | |
Servis et al. | Impact of Irradiation and Decay Time on Chemical Speciation in Uranyl Sulfate Solution | |
RU2270488C2 (en) | Method for radiation treatment of parts and materials by hard gamma-rays | |
Zlokazov et al. | Methodological and engineering approaches to isotope production in the IVV-2M reactor | |
Luo | Preparation of Radionuclides | |
RU2155398C1 (en) | Radioisotope strontium-89 production process | |
Laurinat et al. | Baseline Hypothetical Facility for the Production of 131I, 99Mo, and 133Xe from HALEU Fission Targets | |
Pozdeev et al. | Production of medical 99Mo and molybdenum-technetium generators at the karpov research institute of physical chemistry | |
Van Abel et al. | Design of a Commercial Scale Accelerator Driven Subcritical Aqueous Assembly | |
Shevel | DEVELOPMENT OF THE RADIOISOTOPE PRODUCTION TECHNOLOGIES AT THE WWR-M RESEARCH REACTOR | |
Cieszykowska et al. | SECURE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090508 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100816 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G21G 1/02 20060101AFI20110527BHEP Ipc: G21G 4/08 20060101ALI20110527BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: PROCESS FOR PRODUCING RADIOACTIVE MOLYBDENUM |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 541297 Country of ref document: AT Kind code of ref document: T Effective date: 20120115 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007020050 Country of ref document: DE Effective date: 20120308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20120111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120411 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120511 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120511 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120412 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 541297 Country of ref document: AT Kind code of ref document: T Effective date: 20120111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
26N | No opposition filed |
Effective date: 20121012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007020050 Country of ref document: DE Effective date: 20121012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121031 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20121019 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121031 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121019 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121019 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130501 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007020050 Country of ref document: DE Effective date: 20130501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20131029 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071019 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20150501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150501 |